Brief: Transgene Updates On Phocus Study Of Pexa-Vec In Liver Cancer

Transgene SA

07/08/2019 16:41

Aug 7 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE PROVIDES AN UPDATE AFTER THE INTERIM FUTILITY
ANALYSIS
OF THE PHOCUS STUDY OF PEXA-VEC IN LIVER CANCER
    * TRANSGENE IS CONTINUING TO ADVANCE DEVELOPMENT OF ITS
PROPRIETARY ONCOLYTIC VIRUSES, IN LINE WITH ITS STRATEGY
    * ARE OBVIOUSLY DISAPPOINTED WITH OUTCOME OF PHOCUS STUDY
-CEO
    * WE ALSO EXPECT TO ANNOUNCE THE FIRST CLINICAL DATA WITH
TG6002
IN PATIENTS WITH COLORECTAL CANCER LATER THIS YEAR.  - CEO
    * WE EXPECT TO ANNOUNCE IMPORTANT CLINICAL RESULTS FROM OUR
MOST
ADVANCED THERAPEUTIC VACCINES; TG4010 IN LUNG CANCER AND TG4001
IN HPV-POSITIVE HEAD AND NECK CANCER
    * WITH FUNDING THROUGH TO 2022, CLEAR STRATEGY AND NOVEL
TECHNOLOGY PLATFORMS SUCH AS INVIR.IO® AND MYVAC™, TRANSGENE IS
WELL PLACED - CEO

Source text for Eikon:  ID:nBwbPZ9xla 
Further company coverage:  TRNG.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; 48 58 772 0920;))